How much help does a vaccine-induced T-cell response need?
Weber
J S
JS
Department of Medicine, Keck/University of Southern California School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Mulé
J J
JJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000637:transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D010455:Peptides